PE20061080A1 - Compuestos derivados de piridotienopirimidina como inhibidores de fosfodiesterasa 4 - Google Patents

Compuestos derivados de piridotienopirimidina como inhibidores de fosfodiesterasa 4

Info

Publication number
PE20061080A1
PE20061080A1 PE2005001378A PE2005001378A PE20061080A1 PE 20061080 A1 PE20061080 A1 PE 20061080A1 PE 2005001378 A PE2005001378 A PE 2005001378A PE 2005001378 A PE2005001378 A PE 2005001378A PE 20061080 A1 PE20061080 A1 PE 20061080A1
Authority
PE
Peru
Prior art keywords
pyrane
morpholin
pyrimidin
dihydro
dimethyl
Prior art date
Application number
PE2005001378A
Other languages
English (en)
Inventor
Santacana Lluis Miquel Pages
Joan Taltavull Moll
Jordi Gracia Ferrer
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of PE20061080A1 publication Critical patent/PE20061080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE R1 Y R2 SON H O ALQUILO(C1-C4); n ES 0 O 1; R3 ES ALQUILO(C1-C20), ARILO(C5-C14) MONOCICLICO O POLICICLICO, HETEROARILO DE 5 A 14 MIEMBROS QUE COMPRENDE AL MENOS UN ANILLO HETEROAROMATICO Y QUE CONTIENE UN HETEROATOMO SELECCIONADO DE O, S O N, OPCIONALMENTE SUSTITUIDOS CON HALOGENO, CF3, SO2NH2, ENTRE OTROS; R4 Y R5 SON H, ALQUILO(C1-C20), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2,2-DIMETIL-5-MORFOLIN-4-IL-N-(2-FENETILETIL)-1,4-DIHIDRO-2H-PIRANO[4",3":4',5']PIRIDO[3',2':4,5]TIENO[3,2-d]PIRIMIDIN-8-AMINA, 2,2-DIMETIL-5-MORFOLIN-4-IL-N-(4-METILPIPERIDIN-1-IL)-1,4-DIHIDRO-2H-PIRANO[4",3":4',5']PIRIDO[3',2':4,5]TIENO[3,2-d]PIRIMIDIN-8-AMINA, 2,2-DIMETIL-5-MORFOLIN-4-IL-N-(2-DIETILAMINOETIL)-1,4-DIHIDRO-2H-PIRANO[4",3":4',5']PIRIDO[3',2':4,5]TIENO[3,2-d]PIRIMIDIN-8-AMINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFODIESTERASA 4 SIENDO UTILES EN EL TRATAMIENTO DE ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ARTRITIS REUMATOIDE, PSORIASIS
PE2005001378A 2004-11-30 2005-11-28 Compuestos derivados de piridotienopirimidina como inhibidores de fosfodiesterasa 4 PE20061080A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200402877A ES2259892B1 (es) 2004-11-30 2004-11-30 Nuevos derivados de piridotienopirimidina.

Publications (1)

Publication Number Publication Date
PE20061080A1 true PE20061080A1 (es) 2006-11-10

Family

ID=35064809

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001378A PE20061080A1 (es) 2004-11-30 2005-11-28 Compuestos derivados de piridotienopirimidina como inhibidores de fosfodiesterasa 4

Country Status (19)

Country Link
US (1) US20080207645A1 (es)
EP (1) EP1819712A1 (es)
JP (1) JP2008521854A (es)
KR (1) KR20070086652A (es)
CN (1) CN101068817A (es)
AR (1) AR052413A1 (es)
AU (1) AU2005311422A1 (es)
BR (1) BRPI0518117A (es)
CA (1) CA2588808A1 (es)
ES (1) ES2259892B1 (es)
IL (1) IL183141A0 (es)
MX (1) MX2007006172A (es)
NO (1) NO20073271L (es)
PE (1) PE20061080A1 (es)
RU (1) RU2007124493A (es)
TW (1) TW200631954A (es)
UY (1) UY29240A1 (es)
WO (1) WO2006058723A1 (es)
ZA (1) ZA200703700B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2281251B1 (es) * 2005-07-27 2008-08-16 Laboratorios Almirall S.A. Nuevos derivados de pirido (3',2':4,5) furo (3,2-d) pirimidina.
WO2012131297A1 (en) 2011-03-28 2012-10-04 Jonathan Bayldon Baell Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use
JP2015512862A (ja) 2011-12-21 2015-04-30 インヴィスタ テクノロジーズ エスアエルエル 安定なエマルジョンを減じるための抽出溶媒制御
CN103242276B (zh) * 2013-05-07 2014-07-16 白银安杰利生化科技有限公司 2,2-二甲基四氢-2h-吡喃-4-羧酸的合成方法
BR112018003417B1 (pt) 2016-06-22 2023-10-24 Vanderbilt University Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende
MA46899A (fr) 2016-11-07 2021-04-14 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
MA46722A (fr) 2016-11-07 2019-09-11 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4
JP7099725B2 (ja) 2016-11-07 2022-07-12 ヴァンダービルト ユニヴァーシティ ムスカリン性アセチルコリンレセプターｍ４のポジティブアロステリック調節因子
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
US11376254B2 (en) 2017-12-05 2022-07-05 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
DE19752952A1 (de) * 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
KR20010105399A (ko) * 1999-03-30 2001-11-28 쓰끼하시 다미까따 티에노피리미딘 화합물 및 그의 염, 및 그들의 제조 방법

Also Published As

Publication number Publication date
CN101068817A (zh) 2007-11-07
ZA200703700B (en) 2008-07-30
ES2259892A1 (es) 2006-10-16
MX2007006172A (es) 2007-07-13
NO20073271L (no) 2007-06-26
RU2007124493A (ru) 2009-01-10
KR20070086652A (ko) 2007-08-27
WO2006058723A8 (en) 2007-07-12
WO2006058723A1 (en) 2006-06-08
AR052413A1 (es) 2007-03-21
TW200631954A (en) 2006-09-16
ES2259892B1 (es) 2007-11-01
IL183141A0 (en) 2007-09-20
UY29240A1 (es) 2006-02-24
US20080207645A1 (en) 2008-08-28
EP1819712A1 (en) 2007-08-22
CA2588808A1 (en) 2006-06-08
JP2008521854A (ja) 2008-06-26
BRPI0518117A (pt) 2008-11-04
AU2005311422A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
PE20061080A1 (es) Compuestos derivados de piridotienopirimidina como inhibidores de fosfodiesterasa 4
WO2005092895A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
NO20051694L (no) Heterosykliske forbindelser
BR0308056A (pt) Composto, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para a preparação de um composto
ATE437872T1 (de) Proteinkinaseinhibitoren
ATE427932T1 (de) 11beta-hsd1-inhibitoren
MA29649B1 (fr) Nouveaux derives de 2,4- dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
TW200738682A (en) Isoquinoline derivatives
ATE429427T1 (de) Pyrimidinderivate als orexin-rezeptorantagonisten
BR0214809A (pt) Compostos de pirimidina
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
PE20070362A1 (es) COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk)
PE20070438A1 (es) Derivados de 4-fenil-pirimidina-6-sustituida-2-carbonitrilo como inhibidores de catepsina k y catepsina s
WO2005070884A3 (en) Heterocyclic compounds useful as growth hormone secretagogues
WO2009010789A3 (en) Pyrimidine derivatives 934
PE20061078A1 (es) Derivados de piridotienopirimidina como inhibidores de la fosfodiesterasa 4 (pde4)
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TN2010000173A1 (fr) Antagonistes de cgrp
NO20053018D0 (no) Pyrazoloquinoliner med immunmodulerende aktivitet.
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
MX2009010727A (es) Heterociclos como antagonistas de orexina.
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора

Legal Events

Date Code Title Description
FC Refusal